To confirm the relationship between PARP1 and CDK4/6i resistance over a wider range, we obtained the IC50 for the CDK4/6i palbociclib in 30 breast cancer cell lines from the GDSC database and paired them with corresponding PARP1 mRNA level data gained from CCLE. This evidence concerns the gene PARP1 and breast cancer.